8-KMaterial AgreementsExhibits & Filings

AbbVie Inc. 8-K Report, Material Agreement (Mar 23, 2015)

Filed March 23, 2015For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed a Form 8-K on March 23, 2015, to report an amendment to its previously announced merger agreement with Pharmacyclics, Inc. The amendment, dated March 22, 2015, primarily adjusts the measurement period for AbbVie's common stock price used to determine the merger consideration per share of Pharmacyclics common stock. This filing is crucial for investors as it signifies a modification in the financial terms of a significant acquisition, potentially impacting the final value exchanged for Pharmacyclics. While the core terms of the merger remain intact, the change in the stock price averaging period is a key detail that investors in both companies should monitor. The filing also serves as a reminder that the tender offer for Pharmacyclics has not yet commenced and directs stakeholders to future SEC filings, including the Schedule TO and Form S-4 from AbbVie, and Schedule 14D-9 from Pharmacyclics, which will contain more comprehensive information regarding the transaction. Investors are strongly advised to review these forthcoming documents for a full understanding of the deal's implications.

Key Highlights

  • 1AbbVie Inc. filed an 8-K on March 23, 2015, reporting an amendment to the merger agreement with Pharmacyclics, Inc.
  • 2The amendment, dated March 22, 2015, modifies the calculation methodology for merger consideration related to AbbVie's stock price.
  • 3This amendment specifically adjusts the trading price measurement period used to determine the per-share value of Pharmacyclics.
  • 4The original merger agreement, entered into on March 4, 2015, remains in effect except for the specified modifications.
  • 5The filing serves as a notification that the tender offer for Pharmacyclics has not yet commenced.
  • 6Investors are directed to future SEC filings (Schedule TO, Form S-4, Schedule 14D-9) for detailed information on the tender offer and merger.
  • 7The company provided forward-looking statements with associated risks, including potential challenges to the transaction's consummation and expected benefits.

Frequently Asked Questions

This 8-K filing is primarily to report an amendment to the merger agreement between AbbVie and Pharmacyclics. The amendment adjusts how AbbVie's stock price is measured to determine the final merger consideration for Pharmacyclics shareholders.

The amendment modifies the period over which AbbVie's common stock price is averaged to calculate the merger consideration. This could potentially alter the final value received by Pharmacyclics shareholders depending on the stock price fluctuations during the new measurement period.

According to the filing, the tender offer referenced has not yet commenced. AbbVie and its acquisition subsidiary will file the necessary tender offer statement (Schedule TO) and other related documents with the SEC when the offer is ready to begin.

AbbVie directs investors to future SEC filings, including a Schedule TO and Form S-4 from AbbVie, and a Schedule 14D-9 from Pharmacyclics. These documents will contain important information about the tender offer and merger, and will be available on the SEC's website (www.sec.gov) or through AbbVie Investor Relations.